Mumbai-based pharmaceutical firm, Lupin, has announced plans for a new manufacturing plant in Coral Springs, Florida, US.
With a projected cumulative investment of $250-mn, including research & development, infrastructure and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines.
This move aims to bolster its US respiratory business and diversify its supply chain. The company stated that the project will “enhance medicine security” and reinforce its position as a global leader in respiratory care.
“This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin’s headquarters and our Advanced Inhalation Research Centre,” said Mr. Christoph Funke, Chief Technical Operations Officer, Lupin.
Lupin said the new will anchor US production of critical respiratory therapies, diversify the supply chain, and ensure affordable, reliable access—from routine paediatric care to pandemic-scale demand. Lupin has acquired more than 5 acres of land to embark on this expansion of 70,000 square feet.
In recognition of its investment and job creation plans, Lupin will receive tax credits and incentives from the state of Florida.


10 October, 2025 16:14:20 IST 
















